Nuvation Bio INC. (NUVB) — 10-Q Filings

All 10-Q filings from Nuvation Bio INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Nuvation Bio's Q3 Loss Widens, Revenue Jumps on Product Launch — Nov 3, 2025 Risk: high
Nuvation Bio Inc. reported a net loss of $55.79 million for the three months ended September 30, 2025, an increase from a net loss of $41.21 million in the same
Nuvation Bio's Q2 Loss Widens Amid Rising R&D Spend — Aug 7, 2025 Risk: high
Nuvation Bio Inc. reported a net loss of $58.3 million for the three months ended June 30, 2025, a significant increase from the $48.9 million net loss in the p
Nuvation Bio Files Q1 2025 10-Q Report — May 7, 2025 Risk: medium
Nuvation Bio Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly Panacea Acquisition Corp, is focused on pharmaceutical
Nuvation Bio Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
Nuvation Bio Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Panacea Acquisition Corp., reported financial data for the thir
Nuvation Bio Files Q2 2024 10-Q — Aug 5, 2024 Risk: medium
Nuvation Bio Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition, including cash equivalents and marketable
Nuvation Bio Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk:
Nuvation Bio Inc. (NUVB) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Nuvation Bio Inc. filed a 10-Q report for the period ending March 31, 202

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX